heartandhealth

Heart and Health

6 Months ago

Further evidence does not support hydroxychloroquine for patients with COVID-19: Adverse events were more common in those receiving the drug

The anti-inflammatory drug hydroxychloroquine does not significantly reduce admission to intensive care or death in patients hospitalized with pneumonia due to COVID-19, finds a study from France. And a randomized clinical trial from China shows that hospitalized patients with mild to moderate persistent covid-19 who received hydroxychloroquine did not clear the virus more quickly than those receiving standard care.

  • 0 Likes

  • 0 Comments